New therapy for Enlarged Prostate

[broker]

Its called “ Rezum “. It evaaporates excess prostate tissue using Steam. Its a very quick procedure that can be done right in the doctors office.
No issues with incontinence, no erection issues, no ejaculaion issues.
Another procedure called Uro Lift also has no side effects.
They say the results are excellent.

 

[Vince]

It is evident that the Rezum system has many strengths that endorse its use. Despite this, it is not without its disadvantages. A significant benefit of TURP is its use in incidental identification of prostate cancer, with positive detection on 4.1–16.7% of TURP specimens.17 In contrast, Rezum does not collect tissue specimens; therefore, it lacks the ability to ascertain incidental cases of prostate cancer. Furthermore, the nature of the exclusion criteria limits the number of patients who qualify for the procedure. Patients with urinary retention and large prostate burdens potentially would not be eligible, excluding a significant section of patient population.
Catheterization post procedure is at the discretion of the clinician. In a pilot trial by Dixon and colleagues,8 55% of patients were catheterized prior to discharge plus an additional 17% requiring catheterization post discharge, with an average duration of catheter use of 4.1 days. Of note, many of the sites involved in this trial adopted default position of catheter placement.
There is a lack of long-term follow up; currently, there is only one RCT providing data for a period up to 36 months as part of a 5-year trial.10 It can be argued that further evidence and longer-term data are required to demonstrate that the benefits provided by Rezum can be sustained. Furthermore, all evidence collected to date has been sponsored by NxThera (Maple Grove, MN, USA), which is a potential be a conflict of interest.

Rezum: a new transurethral water vapour therapy for benign prostatic hyperplasia

 

[broker]

Vince
This is a bit more recent.

MARLBOROUGH, Mass., Jan. 25, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that datafrom a randomized clinical trial demonstrate that Rezūm™ Water Vapor Therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH), provides durable results and preserves sexual function four years after treatment. The study, published online ahead of print by Urology, found that patients continued to experience significant and sustained improvement in their symptoms and quality of life over this period.
BPH, which affects 110 million men worldwide, is an enlargement of the prostate in which prostate adenoma cells form excess tissue that may cause symptoms, which impact a patient's quality of life, such as a frequent and urgent need to urinate.1,2
The Rezūm System treats the symptoms of BPH by using water vapor to kill prostate adenoma cells, leading to the cell remnants being absorbed by the body. The procedure can be performed in a physician's office without general anesthesia in a single visit and does not require implants to be placed in the body. The Rezūm System is included in The American Urological Association's BPH treatment guidelines and now has four-year follow-up data showing it can reduce the size of the prostate in all areas of enlarged prostate zones.
"This four-year study supports the use of the first-of-its-kind Rezūm System as a minimally invasive alternative for men with moderate-to-severe BPH who do not want to rely on pharmaceutical management of their symptoms," said Kevin McVary, MD, FACS, lead author and co-principal investigator of the Rezūm II Trial. "The data demonstrate that this advanced technology can empower urologists to achieve significant clinical improvements and deliver an impactful, durable response for their patients."
Over the four years, the trial showed a surgical retreatment rate of 4.4 percent and no new adverse events noted between years three and four. The clinical results also highlighted continued preservation of sexual function, including no de novo erectile dysfunction reported at four years.
"With this study, we continue to build a strong body of clinical evidence supporting the Rezūm System as the preferred minimally invasive treatment for BPH, providing long-lasting symptom relief, while preserving sexual function," said Dave Pierce, executive vice president and president, MedSurg, Boston Scientific. "More than 35,000 patients have already been successfully treated with the Rezūm System and we have recently worked with major insurance providers to extend coverage of the procedure, providing even more men with access to this transformative technology."